CDW Holding announced, on March 1, that two research papers co-authored by its subsidiary GSP Enterprise Inc (GSP) and Okayama University have been accepted for publication by established scientific journals.

One paper was published by the International Journal of Molecular Sciences and documents the successful use of the anti-Cripto-1 antibody in suppressing cancer cell growth.

The other paper was published by the American Journal of Cancer Research and highlighted the discovery of a new cell line which can be used to test new cancer drugs aimed at targeting cancer stem cells.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook